The Top 5 Biosimilar Articles for the Week of November 27

Number 5: Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.

Number 4: Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).

Number 3: Biosimilar experts highlight the persisting confusion around interchangeability designations for biosimilars, including misunderstandings about the definition of interchangeability and the purpose these labels serve.

Number 2: As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.

Number 1: Sarfaraz K. Niazi, PhD, offers hope for the end of interchangeability labels in the United States in his latest column.

To read all of these articles and more, visit centerforbiosimilars.com.